Show simple item record

dc.contributor.authorAl-Digheari, Ahmed
dc.contributor.authorMahboub, Bassam
dc.contributor.authorTarraf, Hesham
dc.contributor.authorYucel, Taskin
dc.contributor.authorAnnesi-Maesano, Isabella
dc.contributor.authorDoble, Adam
dc.contributor.authorLahlou, Aaicha
dc.contributor.authorTariq, Luqman
dc.contributor.authorAziz, Fayaz
dc.contributor.authorEl Hasnaoui, Abdelkader
dc.date.accessioned2019-12-12T06:46:05Z
dc.date.available2019-12-12T06:46:05Z
dc.date.issued2018
dc.identifier.issn1710-1484
dc.identifier.urihttps://doi.org/10.1186/s13223-018-0298-x
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240937/
dc.identifier.urihttp://hdl.handle.net/11655/16973
dc.description.abstractBackground The SNAPSHOT program provides current data on the allergic rhinitis burden in the adult general population of five Middle Eastern countries (Egypt, Turkey, Kuwait, Saudi Arabia and the United Arab Emirates, the latter three grouped into a Gulf cluster). Methods A multi-country, cross-sectional, epidemiological program conducted by telephone in a random sample of the adult general population; quotas were defined per country demographics. Subjects were screened for allergic rhinitis using the Score For Allergic Rhinitis questionnaire. Current prevalence (last 12 months) was estimated. Disease severity and control were assessed using the Allergic Rhinitis and its Impact on Asthma classification and Rhinitis Control Assessment Test respectively. Quality of sleep, impact on daily activities and quality of life were measured using the Epworth Sleepiness Scale, Sheehan Disability Scale and EuroQol Five-Dimension questionnaire respectively. Multivariate logistic regression analyses were used to investigate risk factors and co-morbidities. Results 1808 of 33,486 subjects enrolled in the SNAPSHOT program fulfilled the case definition for allergic rhinitis. Prevalence was 3.6% [95% CI 3.2–4.0%] in Egypt, 6.4% [95% CI 5.9–6.9%] in Turkey and 6.4% [95% CI 6.0–6.9%] in the Gulf cluster. Risk factors identified were country, co-morbid asthma and income. Subjects with allergic rhinitis reported a significantly lower quality of life compared to the general population (p < 0.0001). Overall, 55% of allergic rhinitis subjects were moderate/severe and 33% were uncontrolled. Both these groups reported impaired quality of life and quality of sleep and increased impairment of daily activities compared to mild/well-controlled subjects (p < 0.0001). Conclusions Although the observed prevalence of allergic rhinitis in these Middle Eastern countries is low compared to western countries, its burden is considerable. Allergic rhinitis in general, and specifically uncontrolled and severe disease, results in a negative impact on quality of life, quality of sleep and daily activities.
dc.relation.isversionof10.1186/s13223-018-0298-x
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleThe Clinical Burden of Allergic Rhinitis in Five Middle Eastern Countries: Results of the Snapshot Program
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAllergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
dc.contributor.departmentKulak Burun Boğaz
dc.identifier.volume14
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record